Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Enterprise Value: 2019-2025

Historic Enterprise Value for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to $9.3 billion.

  • BridgeBio Pharma's Enterprise Value rose 111.58% to $9.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 billion, marking a year-over-year increase of 153.07%. This contributed to the annual value of $4.5 billion for FY2024, which is 31.59% down from last year.
  • BridgeBio Pharma's Enterprise Value amounted to $9.3 billion in Q3 2025, which was up 24.71% from $7.5 billion recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Enterprise Value ranged from a high of $9.3 billion in Q3 2025 and a low of $735.7 million during Q4 2022.
  • Moreover, its 3-year median value for Enterprise Value was $4.5 billion (2024), whereas its average is $5.1 billion.
  • As far as peak fluctuations go, BridgeBio Pharma's Enterprise Value crashed by 90.29% in 2022, and later surged by 796.99% in 2023.
  • Over the past 5 years, BridgeBio Pharma's Enterprise Value (Quarterly) stood at $2.1 billion in 2021, then plummeted by 64.36% to $735.7 million in 2022, then spiked by 796.99% to $6.6 billion in 2023, then tumbled by 31.59% to $4.5 billion in 2024, then surged by 111.58% to $9.3 billion in 2025.
  • Its last three reported values are $9.3 billion in Q3 2025, $7.5 billion for Q2 2025, and $6.0 billion during Q1 2025.